Advertisement

Clinical outcomes of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy: Insights from the Johns Hopkins ARVC Program

      Background

      Previous studies of radiofrequency catheter ablation (RFA) of ventricular tachycardia (VT) in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC), relying on limited numbers of procedures, have not reported VT-free survival in parallel for single and multiple procedures (ie, after the last procedure). Data regarding the impact of RFA on VT burden are scarce.

      Objective

      The purpose of this study was to provide new insights on clinical outcomes based on a large series of VT ablation procedures from the current era in ARVC patients.

      Methods

      We evaluated consecutive patients with definite ARVC who underwent RFA procedures between 2009 and 2019 at our center. We assessed VT-free survival, for single and multiple procedures, and changes in VT burden and antiarrhythmic drugs (AADs) after RFA.

      Results

      Among 116 patients, there were 166 RFA procedures, 106 (63.9%) of which involved epicardial ablation. Cumulative freedom from VT after a single procedure was 68.6% and 49.8% at 1 and 5 years, respectively. Cumulative VT-free survival after multiple procedures was 81.8% and 69.6% at 1 and 5 years, respectively. VT burden per RFA was reduced after vs before ablation (mean 0.7 vs 10.0 events/year; P <.001). Furthermore, VT burden per patient was reduced after last ablation vs before first ablation (mean 0.5 vs 10.9 events/year; P <.001). Use of AADs decreased after ablation (22.2% vs 51.9%; P <.001).

      Conclusion

      In ARVC patients, RFA provided good VT-free survival after a single procedure, with multiple procedures required for more sustained freedom from VT recurrence. Marked reduction in VT burden permitted discontinuation of AADs.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Basso C.
        • Thiene G.
        • Corrado D.
        • et al.
        Arrhythmogenic right ventricular cardiomyopathy: dysplasia, dystrophy, or myocarditis?.
        Circulation. 1996; 94: 983-991
        • Thiene G.
        • Basso C.
        • Calabrese F.
        • Angelini A.
        • Valente M.
        Pathology and pathogenesis of arrhythmogenic right ventricular cardiomyopathy.
        Herz. 2000; 25: 210-215
        • Schinkel A.F.
        Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications.
        Circ Arrhythm Electrophysiol. 2013; 6: 562-568
        • Corrado D.
        • Wichter T.
        • Link M.S.
        • et al.
        Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.
        Eur Heart J. 2015; 36: 3227-3237
        • Verma A.
        • Kilicaslan F.
        • Schweikert R.A.
        • et al.
        Short-and long-term success of substrate-based mapping and ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia.
        Circulation. 2005; 111: 3209-3216
        • Satomi K.
        • Kurita T.
        • Suyama K.
        • et al.
        Catheter ablation of stable and unstable ventricular tachycardias in patients with arrhythmogenic right ventricular dysplasia.
        J Cardiovasc Electrophysiol. 2006; 17: 469-476
        • Dalal D.
        • Jain R.
        • Tandri H.
        • et al.
        Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy.
        J Am Coll Cardiol. 2007; 50: 432-440
        • Philips B.
        • Madhavan S.
        • James C.
        • et al.
        Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy.
        Circ Arrhythm Electrophysiol. 2012; 5: 499-505
        • Wei W.
        • Liao H.
        • Xue Y.
        • et al.
        Long-term outcomes of radio-frequency catheter ablation on ventricular tachycardias due to arrhythmogenic right ventricular cardiomyopathy: a single center experience.
        PLoS One. 2017; 12e0169863
        • Souissi Z.
        • Boulé S.
        • Hermida J.S.
        • et al.
        Catheter ablation reduces ventricular tachycardia burden in patients with arrhythmogenic right ventricular cardiomyopathy: insights from a north-western French multicentre registry.
        Europace. 2018; 20: 362-369
        • Mahida S.
        • Venlet J.
        • Saguner A.M.
        • et al.
        Ablation compared with drug therapy for recurrent ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy: results from a multicenter study.
        Heart Rhythm. 2019; 16: 536-543
        • Mathew S.
        • Saguner A.M.
        • Schenker N.
        • et al.
        Catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia: a sequential approach.
        J Am Heart Assoc. 2019; 8e010365
        • Liang E.
        • Wu L.
        • Fan S.
        • et al.
        Catheter ablation of arrhythmogenic right ventricular cardiomyopathy ventricular tachycardia: 18-year experience in 284 patients.
        Europace. 2020; 22: 806-812
        • Garcia F.C.
        • Bazan V.
        • Zado E.S.
        • et al.
        Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia.
        Circulation. 2009; 120: 366-375
        • Bai R.
        • Di Biase L.
        • Shivkumar K.
        • et al.
        Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate-based mapping and ablation.
        Circ Arrhythm Electrophysiol. 2011; 4: 478-485
        • Berruezo A.
        • Fernández-Armenta J.
        • Mont L.
        • et al.
        Combined endocardial and epicardial catheter ablation in arrhythmogenic right ventricular dysplasia incorporating scar dechanneling technique.
        Circ Arrhythm Electrophysiol. 2012; 5: 111-121
        • Philips B.
        • Te Riele A.S.
        • Sawant A.
        • et al.
        Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy.
        Heart Rhythm. 2015; 12: 716-725
        • Santangeli P.
        • Zado E.S.
        • Supple G.E.
        • et al.
        Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy.
        Circ Arrhythm Electrophysiol. 2015; 8: 1413-1421
        • Berruezo A.
        • Acosta J.
        • Fernández-Armenta J.
        • et al.
        Safety, long-term outcomes and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy. Impact of arrhythmic substrate distribution pattern. A prospective multicentre study.
        Europace. 2017; 19: 607-616
        • Marcus F.I.
        • McKenna W.J.
        • Sherrill D.
        • et al.
        Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria.
        Circulation. 2010; 121: 1533-1541
        • Assis F.R.
        • Tandri H.
        Epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy.
        Card Electrophysiol Clin. 2020; 12: 329-343
        • Fernández-Armenta J.
        • Berruezo A.
        How to recognize epicardial origin of ventricular tachycardias?.
        Curr Cardiol Rev. 2014; 10: 246-256
        • Quinto L.
        • Sanchez-Somonte P.
        • Alarcón F.
        • et al.
        Ventricular tachycardia burden reduction after substrate ablation: predictors of recurrence.
        Heart Rhythm. 2021 Feb 24; (00178-8): S1547-5271
        • Daimee U.A.
        • Berger R.D.
        Success after ventricular tachycardia ablation: all or nothing?.
        Heart Rhythm. 2021 Mar 10; (00205-8): S1547-5271